跳至主要内容
临床试验/JPRN-UMIN000007619
JPRN-UMIN000007619已完成4 期

Efficacy and safety of glycemic control in type 2 diabetes patients when switched to mitiglinide/voglibose fixed-dose combination therapy. - Efficacy and safety of mitiglinide/voglibose fixed-dose combination therapy.

Keio University School of Medicine Department of Nephrology, Endocrinology and Metabolism0 个研究点目标入组 15 人开始时间: 2012年4月1日最近更新:
适应症

试验速览

阶段
4 期
状态
已完成
发起方
入组人数
15

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 ot applicable(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1)Contraindicated for mitiglinide or voglibose. 2)Patients who received glinide or alpha GI more than daily dose*. (Daily dose: mitiglinide 10mg/time, nateglinide 90mg/time, voglibose 0.3mg/time, acarbose 100mg/time, miglitol 50mg/time) 3)Patients who had been previously receiving DPP4 inhibitor or GLP-1 analogue, insulin. 4)Anticipated to be non-compliant to the trial by principal investigators opinion.

研究者

发起方
Keio University School of Medicine Department of Nephrology, Endocrinology and Metabolism

相似试验

Efficacy and safety of glycemic control in type 2... | 临床试验